Artemether-lumefantrine compared to atovaquone-proguanil as a treatment for uncomplicated plasmodium falciparum malaria in travelers

12Citations
Citations of this article
48Readers
Mendeley users who have this article in their library.

Abstract

Atovaquone-proguanil (AP) and artemether-lumefantrine (AL) are both treatments for uncomplicated Plasmodium falciparum malaria, but comparative clinical trials are lacking. We performed a retrospective analysis, comparing treatment failure and fever clearance time in non-immune travelers with uncomplicated P. falciparum malaria, treated with AP or AL. Sixty-nine patients were included during 2001-2013: 44 in the AP group and 25 in the AL group. Treatment failure was observed in 6 of 44 (13.6%) and 1 of 25 (4.0%) patients in the AP and AL groups, respectively. Six treatment failures were observed in travelers from West Africa. Fever clearance time was 44 ± 23 h in AL group versus 77 ± 28 h in AP group, (P < 0.001). Hospitalization time was significantly shorter in the AL group; 3.8 + 1.3 versus 5.1 + 2.8 days in the AP group (P = 0.04) In conclusion, travelers with uncomplicated P. falciparum malaria recover faster on AL than on AP. The AL should probably be the drug of choice for this population.

Cite

CITATION STYLE

APA

Grynberg, S., Lachish, T., Kopel, E., Meltzer, E., & Schwartz, E. (2015). Artemether-lumefantrine compared to atovaquone-proguanil as a treatment for uncomplicated plasmodium falciparum malaria in travelers. American Journal of Tropical Medicine and Hygiene, 92(1), 13–17. https://doi.org/10.4269/ajtmh.14-0249

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free